Early Detection of Myelodysplastic Syndrome/Leukemia-associated Mutations Using NGS Is Critical in Treating Aplastic Anemia

Overview

Journal Curr Med Sci

Specialty General Medicine

Date 2019 Apr 25

PMID 31016513

Citations 2

Authors

Xiang Li

Yao-Hui Wu

Si-Si Cai

Wei-Ming Li

Yong You

Min Zhang

Affiliations

Soon will be listed here.

Abstract

Distinguishing between aplastic anemia (AA) and hypoblastic myelodysplastic syndrome (hMDS) with a low percentage of bone marrow (BM) blasts (<5%) can be difficult due to the overlap in clonality and a spectrum of genetic alternations between the two subtypes of diseases. However, due to recent advances in DNA sequencing technology, both spectrum and frequency of mutations can be accurately determined and monitored by next-generation sequencing (NGS) at initial diagnosis and during immunosuppressive therapy (IST) in patients with AA or hMDS. This improvement in acquiring a patient's genetic status and clonal evolution can provide more proper, precise, and on-time information to guide disease management, which is especially helpful in the absence of traditional morphologic/cytogenetic evidence.

Citing Articles

Severe aplastic anemia with acquired X chromosome clonality as a sole abnormality.

Jang T, Burnside R, Chaffin J, Seifert R, Hiemenz J Ann Hematol. 2024; 104(1):815-819.

PMID: 39738592 DOI: 10.1007/s00277-024-06166-0.

Unraveling trajectories from aplastic anemia to hematologic malignancies: genetic and molecular insights.

Kim N, Choi Y, Lee S, Choi J, Lyu C, Shin S Front Oncol. 2024; 14:1365614.

PMID: 38544839 PMC: 10965666. DOI: 10.3389/fonc.2024.1365614.

References

Steensma D, Dispenzieri A, Moore S, Schroeder G, Tefferi A . Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood. 2002; 101(6):2156-8. DOI: 10.1182/blood-2002-09-2867. View

Killick S, Mufti G, Cavenagh J, Mijovic A, Peacock J, Gordon-Smith E . A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol. 2003; 120(4):679-84. DOI: 10.1046/j.1365-2141.2003.04136.x. View

Marisavljevic D, Cemerikic V, Rolovic Z, Boskovic D, Colovic M . Hypocellular myelodysplastic syndromes: clinical and biological significance. Med Oncol. 2005; 22(2):169-75. DOI: 10.1385/MO:22:2:169. View

Lim Z, Killick S, Germing U, Cavenagh J, Culligan D, Bacigalupo A . Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia. 2007; 21(7):1436-41. DOI: 10.1038/sj.leu.2404747. View

Passweg J, Giagounidis A, Simcock M, Aul C, Dobbelstein C, Stadler M . Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. J Clin Oncol. 2010; 29(3):303-9. DOI: 10.1200/JCO.2010.31.2686. View

Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O . Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011; 25(7):1147-52. DOI: 10.1038/leu.2011.71. View

Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G . Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011; 364(26):2496-506. PMC: 3159042. DOI: 10.1056/NEJMoa1013343. View

Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R . Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478(7367):64-9. DOI: 10.1038/nature10496. View

Afable 2nd M, Tiu R, Maciejewski J . Clonal evolution in aplastic anemia. Hematology Am Soc Hematol Educ Program. 2011; 2011:90-5. DOI: 10.1182/asheducation-2011.1.90. View

10.

Bejar R, Stevenson K, Caughey B, Abdel-Wahab O, Steensma D, Galili N . Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012; 30(27):3376-82. PMC: 3438234. DOI: 10.1200/JCO.2011.40.7379. View

11.

Lane A, Odejide O, Kopp N, Kim S, Yoda A, Erlich R . Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia. 2013; 27(4):968-71. PMC: 4552245. DOI: 10.1038/leu.2013.30. View

12.

Damm F, Chesnais V, Nagata Y, Yoshida K, Scourzic L, Okuno Y . BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood. 2013; 122(18):3169-77. DOI: 10.1182/blood-2012-11-469619. View

13.

Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G . Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2013; 28(2):241-7. PMC: 3918868. DOI: 10.1038/leu.2013.336. View

14.

Shlush L, Zandi S, Mitchell A, Chen W, Brandwein J, Gupta V . Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014; 506(7488):328-33. PMC: 4991939. DOI: 10.1038/nature13038. View

15.

Heuser M, Schlarmann C, Dobbernack V, Panagiota V, Wiehlmann L, Walter C . Genetic characterization of acquired aplastic anemia by targeted sequencing. Haematologica. 2014; 99(9):e165-7. PMC: 4562551. DOI: 10.3324/haematol.2013.101642. View

16.

Kim S, Le Rademacher J, Antin J, Anderlini P, Ayas M, Battiwalla M . Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. Haematologica. 2014; 99(12):1868-75. PMC: 4258748. DOI: 10.3324/haematol.2014.108977. View

17.

Kulasekararaj A, Jiang J, Smith A, Mohamedali A, Mian S, Gandhi S . Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood. 2014; 124(17):2698-704. PMC: 4383793. DOI: 10.1182/blood-2014-05-574889. View

18.

Bejar R, Lord A, Stevenson K, Bar-Natan M, Perez-Ladaga A, Zaneveld J . TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014; 124(17):2705-12. PMC: 4208285. DOI: 10.1182/blood-2014-06-582809. View

19.

Xie M, Lu C, Wang J, McLellan M, Johnson K, Wendl M . Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014; 20(12):1472-8. PMC: 4313872. DOI: 10.1038/nm.3733. View

20.

Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman P, Mar B . Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26):2488-98. PMC: 4306669. DOI: 10.1056/NEJMoa1408617. View